What is Micrima?
Founded in 2006 and headquartered in Bristol, UK, Micrima Ltd. is at the forefront of developing novel radio-wave technology aimed at improving the accuracy and accessibility of breast cancer detection. The company's proprietary technology seeks to offer a non-invasive and potentially more effective alternative to existing screening methods. By leveraging advanced radio-wave physics, Micrima aims to provide clinicians with enhanced diagnostic capabilities, ultimately contributing to earlier and more precise cancer identification.
How much funding has Micrima raised?
Micrima has raised a total of $14.2M across 3 funding rounds:
Unspecified
$3.4M
Private Equity
$5.6M
Unspecified
$5.2M
Unspecified (2016): $3.4M with participation from Technology Venture Partners, Angel CoFund, Swarraton Partners, and University of Bristol Enterprise Fund
Private Equity (2018): $5.6M led by Technology Venture Partners, Venture Founders, and Angel CoFund
Unspecified (2021): $5.2M supported by Technology Venture Partners LLC
Key Investors in Micrima
Technology Venture Partners LLC
Technology Venture Partners LLC is an investment entity that likely focuses on technology-driven companies, potentially in the early to growth stages, given its participation in various funding rounds.
Angel CoFund
Angel CoFund is a UK-based investment fund that partners with angel investors to support promising businesses, indicating a focus on early-stage and growth-stage companies with high potential.
Technology Venture Partners
Technology Venture Partners is a venture capital firm specializing in the technology sector, likely providing strategic investment and operational support to companies aiming for significant market impact.
What's next for Micrima?
The recent major strategic investment positions Micrima for accelerated growth and further development of its groundbreaking breast cancer detection technology. This capital infusion is expected to fuel advancements in research and development, potentially leading to broader clinical trials and regulatory approvals. With a clear trajectory supported by consistent funding, Micrima is poised to scale its operations and introduce its innovative solution to a wider market, aiming to make a significant impact on global breast cancer screening protocols.
See full Micrima company page
